Last reviewed · How we verify
NCT06286839
Study of Cannabidiol (CBD) in Healthy Volunteers
NA trial testing Cannabidiol (CBD) in Immune System and Related Disorders in 26 participants. Completed in 14 December 2022.
28 October 2022
Quick facts
| Lead sponsor | NextEvo Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 26 |
| Start date | 12 May 2022 |
| Primary completion | 28 October 2022 |
| Estimated completion | 14 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Cannabidiol (CBD) — full drug profile →
Conditions studied
- Immune System and Related Disorders — all drugs for Immune System and Related Disorders →
- Immune System Diseases — all drugs for Immune System Diseases →
Sponsor
NextEvo Inc.
Who can join
Adults 18 to 45, any sex, with Immune System and Related Disorders or Immune System Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This was a prospective, single-centre, open label, randomized, two-arm, parallel design study to evaluate the effect of four-weeks consumption of active study product on primary endpoint in healthy adults
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06286839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cannabidiol (CBD)
Trials testing the same drug.
- NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT06994520 — Efficacy of Topical Cannabidiol for Eczema · Phase 2 · active not recruiting
- NCT05753007 — A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients · Phase 2 · terminated
- NCT05836857 — The Use of Cannabis (Marijuana) and Cannabidiol (CBD) Among Cancer Patients: A Pilot Study · active not recruiting
Other recruiting trials for Immune System and Related Disorders
Currently open trials in the same condition.
- NCT06930976 — Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells · NA · recruiting
- NCT06051461 — Deciphering the Role of Dietary Fatty Acids on Extracellular Vesicles-mediated Intercellular Communication · NA · active not recruiting
- NCT06390696 — Sand Play - the Effect of Biodiversity Exposure on Atopic Dermatitis · NA · recruiting
- NCT06390683 — Biodiversity Interventions for Assisted Living Centers · NA · active not recruiting
- NCT05306925 — An Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06286839 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NextEvo Inc.
- Last refreshed: 29 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06286839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing